Efficacy of radiation therapy for incompletely resected grade-III mast cell tumors in dogs: 31 cases (1987-1998).
OBJECTIVE
To determine the efficacy (durations of remission and survival) of an alternating-day radiation protocol for incompletely excised histologic grade-III solitary mast cell tumors (MCTs) in dogs.


METHODS
Retrospective study.


METHODS
31 dogs.


METHODS
Radiation (52 Gy in an 18-fraction alternating-day protocol) was delivered to an area bordered by margins > or = 3 cm around the surgical scar and to the associated local-regional lymph nodes. Dogs were not given chemotherapeutic agents concurrently or after radiation. Information on signalment, duration of remission, and survival time was obtained from medical records.


RESULTS
Median and mean durations of remission were 27.7 and 17.0 months, respectively (range, 1 to 47 months). Median and mean durations of survival were 28 and 20 months, respectively (range, 3 to 52 months). Dogs with tumors located on the skin of the pinna, perineum, and prepuce had a median duration of remission greater than dogs with tumors located at other sites (27.7 and 14.4 months, respectively). Dogs with tumors < or = 3 cm in maximum diameter before surgery survived longer than dogs with tumors > 3 cm (31 and 24 months, respectively). The remission rate was 65% and survival rate was 71% at 1 year after treatment. Sixteen dogs that were euthanatized had complications associated with local-regional tumor progression. Systemic metastases to liver, spleen, intestine, and bone marrow were detected in 1 dog.


CONCLUSIONS
Without further treatment, incompletely excised grade-III mast cell tumors have high local-regional recurrence; local-regional treatment with radiation may effectively be used to manage many such tumors.
Hahn
Kevin A
KA
Gulf Coast Veterinary Oncologists 1111 W Loop South, Ste 150, Houston, TX 77027, USA.
King
Glen K
GK
Carreras
Janet K
JK
D000818:Animals; D018572:Disease-Free Survival; D004283:Dog Diseases / Q000401:mortality / Q000532:radiotherapy*; D004285:Dogs; D005260:Female; D008297:Male; D012515:Mast-Cell Sarcoma / Q000401:mortality / Q000532:radiotherapy / Q000662:veterinary*; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000532:radiotherapy / Q000662:veterinary*; D009367:Neoplasm Staging; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000401:mortality / Q000532:radiotherapy / Q000662:veterinary*; D016896:Treatment Outcome